Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc.INDV · Entity 4040 | Chief Financial Officer | June 08, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Indivior Pharmaceuticals, Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 284,751 |
Reported balance
After 2026-06-08 transaction · row 1
1 source rowRow 1 · 2026-06-08 · Sale · Disposed 36,000 · Balance 284,751 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 10, 2026 10:04 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | SaleCommon Stock | 36,000 | $37.70 | $1,357,200.00 |
DisclosureSEC source: 0002014866-26-000011 · wk-form4_1781085864.xml · nonDerivative · entry 1 Preblick Ryan · CIK 0002014866 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,751 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 20:32 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | Exercise / conversionRestricted Stock Units · Derivative | 6,302 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0002014866-26-000008 · wk-form4_1773779535.xml · derivative · entry 3 Preblick Ryan · CIK 0002014866 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units (RSUs) convert into shares of the Issuer's common stock on a one-for-one basis. F1 · price: Restricted stock units (RSUs) convert into shares of the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 14, 2024, the reporting person was granted 6,302 RSUs in accordance with the Indivior Group Deferred Bonus Plan 2018. Those RSUs vested in a single installment on March 14, 2026. F3 · derivative.expiration_date: On March 14, 2024, the reporting person was granted 6,302 RSUs in accordance with the Indivior Group Deferred Bonus Plan 2018. Those RSUs vested in a single installment on March 14, 2026. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 20:32 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | Tax withholdingCommon Stock | 2,843 | $31.11 | $88,445.73 |
DisclosureSEC source: 0002014866-26-000008 · wk-form4_1773779535.xml · nonDerivative · entry 2 Preblick Ryan · CIK 0002014866 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,751 F2 · shares: Shares used to satisfy tax withholding obligations associated with the vesting of RSUs on March 14, 2026. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 20:32 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | Exercise / conversionCommon Stock | 6,302 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002014866-26-000008 · wk-form4_1773779535.xml · nonDerivative · entry 1 Preblick Ryan · CIK 0002014866 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units (RSUs) convert into shares of the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:00 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | Exercise / conversionPerformance Stock Units · Derivative | 113,510 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0002014866-26-000006 · wk-form4_1772744411.xml · derivative · entry 3 Preblick Ryan · CIK 0002014866 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,510 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 76.6% with respect to the performance stock units granted to the Reporting Person on March 3, 2023, of which 86,949 shares vested out of the 113,510 target amount. These shares will be released following a two-year holding period. F2 · derivative.expiration_date: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 76.6% with respect to the performance stock units granted to the Reporting Person on March 3, 2023, of which 86,949 shares vested out of the 113,510 target amount. These shares will be released following a two-year holding period. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:00 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | Exercise / conversionCommon Stock | 86,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002014866-26-000006 · wk-form4_1772744411.xml · nonDerivative · entry 2 Preblick Ryan · CIK 0002014866 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 76.6% with respect to the performance stock units granted to the Reporting Person on March 3, 2023, of which 86,949 shares vested out of the 113,510 target amount. These shares will be released following a two-year holding period. F3 · price: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:00 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | Tax withholdingCommon Stock | 87,597 | $31.98 | $2,801,352.06 |
DisclosureSEC source: 0002014866-26-000006 · wk-form4_1772744411.xml · nonDerivative · entry 1 Preblick Ryan · CIK 0002014866 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,343 F1 · shares: In 2024, 204,904 shares vested in respect of performance stock units granted to the Reporting Person on March 3, 2021. These shares were subject to a further two-year holding period. On March 3, 2026, the holding period ended and 87,597 shares were withheld to satisfy tax withholding obligations. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:07 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | GrantCommon Stock | 37,358 | $0.00 | $0.00 |
DisclosureSEC source: 0002014866-26-000004 · wk-form4_1770930440.xml · nonDerivative · entry 1 Preblick Ryan · CIK 0002014866 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,940 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 21:07 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | GrantPerformance Stock Units · Derivative | 113,510 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002014866-26-000004 · wk-form4_1770930440.xml · derivative · entry 2 Preblick Ryan · CIK 0002014866 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,510 Underlying: Common Stock · 113,510 shares Expires not disclosed F2 · derivative.exercise_date: On March 3, 2023, the Reporting Person was granted a conditional award for 113,510 shares, subject to satisfaction of performance conditions, which were certified on February 9, 2026. The award vests, subject to continued employment conditions, on March 3, 2026. The shares will then be subject to an additional two-year Holding Period before the vested Shares are released to the Reporting Person. F2 · derivative.expiration_date: On March 3, 2023, the Reporting Person was granted a conditional award for 113,510 shares, subject to satisfaction of performance conditions, which were certified on February 9, 2026. The award vests, subject to continued employment conditions, on March 3, 2026. The shares will then be subject to an additional two-year Holding Period before the vested Shares are released to the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.